Obesity drug developer Aardvark Therapeutics (AARD) has filed for a $100M initial public offering. Aardvark (AARD) didn't disclose any terms in its SEC filing, but indicated in its filing fee schedule ...

Bank stocks have been on a post-election upswing, with the KBW Nasdaq Bank Index ( ^BKX) up 14% since Trump won the ...

Ladies and gentlemen, thank you for standing by. My name is Abby and I'll be your conference operator today. (Operator Instructions) Thank you. And I would now like to turn the conference over to ...

RBC Capital analyst Kenneth Herbert maintained a Buy rating on Boeing (BA – Research Report) today and set a price target of $200.00. The ...

In a report released today, James Edwardes Jones from RBC Capital maintained a Buy rating on Reckitt (RKT – Research Report), with a price ...

Hello! It’s Matt Monks in New York, chatting with the top insurance services M&A banker in finance, who walks us through the deal boom in the sector. Elsewhere, Mideast money draws a crowd in Davos ...

Morgan Stanley will work with the U.S. Treasury and other regulators to figure out how it can offer crypto in a safe way ...

Charting, Price Performance, News & Related Contracts.

RBC BlueBay Asset Management’s hedge fund is seeing an opportunity to profit from volatility during US President Donald Trump’s second term, after outperforming the industry in a difficult period for ...

Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $14.55 which represents a slight increase of $0.42 or 2.97% from the prior close of $14.13. The stock opened at $14.3 and ...

Barry Callebaut (SIX: BARN) reported lower sales volume in the first quarter of their 2025 fiscal year, as expected by the ...

Hedge funds have positioned for Donald Trump's U.S. presidency with their highest levels of borrowing since 2010, while ...